<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422876</url>
  </required_header>
  <id_info>
    <org_study_id>1275.1</org_study_id>
    <secondary_id>2011-000383-10</secondary_id>
    <nct_id>NCT01422876</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients</brief_title>
  <official_title>A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination
      (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to
      support approval by regulatory authorities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 24 for Metformin Background Patients</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
    <description>Change from baseline in fasting plasma glucose at week 24 for Metformin Background patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 24 for Treatment Naive Patients</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
    <description>Change from baseline in fasting plasma glucose at week 24 for Treatment Naive patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight for Metformin Background Patients</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
    <description>Change from baseline in body weight for Metformin Background patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight for Treatment Naive Patients</measure>
    <time_frame>Baseline and 24 Weeks</time_frame>
    <description>Change from baseline in body weight for Treatment Naive patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treat to Target Efficacy Response for Metformin Background Patients</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Occurrence of the treat-to-target efficacy response for Metformin Background patients measured as HbA1c &lt; 7.0% after 24 weeks of treatment for patients with HbA1c &gt;=7.0% at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Occurrence of the treat-to-target efficacy response for Treatment Naive patients measured as HbA1c &lt; 7.0% after 24 weeks of treatment for patients with HbA1c &gt;=7.0% at baseline.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1405</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773/linagliptin FDC (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773/linagliptin FDC (high dose) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773/linagliptin FDC (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BI 10773/linagliptin FDC (low dose) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 (high dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive BI 10773 (high dose) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 (low dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive BI 10773 (low dose) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive linagliptin once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose FDC</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 high dose</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose BI 10773 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose FDC</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 low dose</intervention_name>
    <description>low dose once daily</description>
    <arm_group_label>BI 10773 (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose BI 10773 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose BI 10773 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin</intervention_name>
    <description>once daily</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose FDC placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 low dose placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose BI 10773 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773 (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose BI 10773 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 low dose placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose BI 10773 placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 10773/linagliptin FDC (low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent

          2. Male and female patients on diet and exercise regimen who are drug-naïve (defined as
             absence of any oral antidiabetic therapy, glucagon like peptide-1 analog or insulin
             for 12 weeks prior to randomization) or pre-treated with metformin (=1500 mg/day or on
             the maximum tolerated dose or the maximum dose according to local label) unchanged for
             12 weeks prior to randomisation.

          3. Glycosylated hemoglobin (HbA1c) = 7.0% and = 10.5% (= 53.0 mmol/mol and = 91.3
             mmol/mol) at Visit 1 (screening)

        Exclusion criteria:

          1. Uncontrolled hyperglycemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an
             overnight fast during placebo run-in and confirmed by a second measurement (not on the
             same day).

          2. Any other antidiabetic drug within 12 weeks prior to randomization (except metformin
             background therapy as defined via inclusion criterion 2)

          3. Acute coronary syndrome (non-ST elevation myocardial infarction, ST elevation
             myocardial infarction and unstable angina pectoris), stroke or (transient ischemic
             attack) TIA within 3 months prior to informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1275.1.01103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01089 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01086 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harbor City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01090 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01092 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01094 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01099 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groveport</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01088 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01093 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hodges</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spring Hill</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01096 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Chesterfield</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selah</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shoreline</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.01119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Ringwood</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joaquim Távora</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.59003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.59006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.59004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.57004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.57005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.57002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.57003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tolima</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.37206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kivioli</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.37204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viljandi County</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyongyos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bassano del Grappa (VI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.96004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baabda</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.96002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.96003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.96006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.96008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.96007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kedah</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.52005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Luis Potosí</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.51001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.51003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ica</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.51002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.51004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.51005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenhills, San Juan</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marikina city</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasay City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baia Mare Maramures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet de Llobegrat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Järfälla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rättvik</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skene</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88006 Chang Gung Memorial Hospital-CY</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88007 E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88001 Cardinal Tien Hospital</name>
      <address>
        <city>New Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88004 Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88008 Chi Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88002 Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.1.88003 Taipei Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Korea, Republic of</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Boehringer Ingelheim Global Clinical Trials Website</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>April 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2015</results_first_posted>
  <disposition_first_submitted>May 15, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 15, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 28, 2014</disposition_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 1405 patients enrolled and randomized the data for 42 randomized patients were excluded from all analyses due to serious non-compliance. Therefore, 1363 patients were included in the analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation. Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin: Oral</description>
        </group>
        <group group_id="P2">
          <title>Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P3">
          <title>Metformin Background: Empagliflozin 25 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P4">
          <title>Metformin Background: Empagliflozin 10 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P5">
          <title>Metformin Background: Linagliptin 5 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P6">
          <title>Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P7">
          <title>Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P8">
          <title>Treatment Naive: Empagliflozin 25 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P9">
          <title>Treatment Naive: Empagliflozin 10 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="P10">
          <title>Treatment Naive: Linagliptin 5 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="141"/>
                <participants group_id="P4" count="140"/>
                <participants group_id="P5" count="132"/>
                <participants group_id="P6" count="137"/>
                <participants group_id="P7" count="136"/>
                <participants group_id="P8" count="135"/>
                <participants group_id="P9" count="134"/>
                <participants group_id="P10" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="136"/>
                <participants group_id="P4" count="132"/>
                <participants group_id="P5" count="125"/>
                <participants group_id="P6" count="131"/>
                <participants group_id="P7" count="130"/>
                <participants group_id="P8" count="128"/>
                <participants group_id="P9" count="128"/>
                <participants group_id="P10" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="141"/>
                <participants group_id="P4" count="140"/>
                <participants group_id="P5" count="132"/>
                <participants group_id="P6" count="137"/>
                <participants group_id="P7" count="136"/>
                <participants group_id="P8" count="135"/>
                <participants group_id="P9" count="134"/>
                <participants group_id="P10" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="128"/>
                <participants group_id="P4" count="122"/>
                <participants group_id="P5" count="117"/>
                <participants group_id="P6" count="120"/>
                <participants group_id="P7" count="120"/>
                <participants group_id="P8" count="112"/>
                <participants group_id="P9" count="113"/>
                <participants group_id="P10" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="17"/>
                <participants group_id="P7" count="16"/>
                <participants group_id="P8" count="23"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="13"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation and treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
. Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B2">
          <title>Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation and treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B3">
          <title>Metformin Background: Empagliflozin 25 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation and treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B4">
          <title>Metformin Background: Empagliflozin 10 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation and treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B5">
          <title>Metformin Background: Linagliptin 5 mg</title>
          <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation and treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B6">
          <title>Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B7">
          <title>Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B8">
          <title>Treatment Naive: Empagliflozin 25 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B9">
          <title>Treatment Naive: Empagliflozin 10 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B10">
          <title>Treatment Naive: Linagliptin 5 mg</title>
          <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="140"/>
            <count group_id="B4" value="137"/>
            <count group_id="B5" value="128"/>
            <count group_id="B6" value="134"/>
            <count group_id="B7" value="135"/>
            <count group_id="B8" value="133"/>
            <count group_id="B9" value="132"/>
            <count group_id="B10" value="133"/>
            <count group_id="B11" value="1341"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="10.2"/>
                    <measurement group_id="B2" value="56.2" spread="10.3"/>
                    <measurement group_id="B3" value="55.5" spread="10.0"/>
                    <measurement group_id="B4" value="56.1" spread="10.5"/>
                    <measurement group_id="B5" value="56.2" spread="10.0"/>
                    <measurement group_id="B6" value="54.2" spread="10.0"/>
                    <measurement group_id="B7" value="55.2" spread="9.8"/>
                    <measurement group_id="B8" value="56.0" spread="9.3"/>
                    <measurement group_id="B9" value="53.9" spread="10.5"/>
                    <measurement group_id="B10" value="53.8" spread="11.5"/>
                    <measurement group_id="B11" value="55.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="62"/>
                    <measurement group_id="B8" value="56"/>
                    <measurement group_id="B9" value="68"/>
                    <measurement group_id="B10" value="58"/>
                    <measurement group_id="B11" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="70"/>
                    <measurement group_id="B7" value="73"/>
                    <measurement group_id="B8" value="77"/>
                    <measurement group_id="B9" value="64"/>
                    <measurement group_id="B10" value="75"/>
                    <measurement group_id="B11" value="721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients</title>
        <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all Metformin Background patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Metformin Background: Empagliflozin 25 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Metformin Background: Empagliflozin 10 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Metformin Background: Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients</title>
          <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.</description>
          <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all Metformin Background patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
          <units>% change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.06"/>
                    <measurement group_id="O2" value="-1.08" spread="0.06"/>
                    <measurement group_id="O3" value="-0.62" spread="0.06"/>
                    <measurement group_id="O4" value="-0.66" spread="0.06"/>
                    <measurement group_id="O5" value="-0.70" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0038), geographical region (p&lt;0.0001), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0038), geographical region (p&lt;0.0001), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0038), geographical region (p&lt;0.0001), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0038), geographical region (p&lt;0.0001), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 24 for Metformin Background Patients</title>
        <description>Change from baseline in fasting plasma glucose at week 24 for Metformin Background patients.</description>
        <time_frame>Baseline and 24 Weeks</time_frame>
        <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all Metformin Background patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Metformin Background: Empagliflozin 25 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Metformin Background: Empagliflozin 10 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Ora</description>
          </group>
          <group group_id="O5">
            <title>Metformin Background: Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 24 for Metformin Background Patients</title>
          <description>Change from baseline in fasting plasma glucose at week 24 for Metformin Background patients.</description>
          <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all Metformin Background patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
          <units>mg/dL change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="136"/>
                <count group_id="O5" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.25" spread="2.53"/>
                    <measurement group_id="O2" value="-32.18" spread="2.52"/>
                    <measurement group_id="O3" value="-18.83" spread="2.47"/>
                    <measurement group_id="O4" value="-20.84" spread="2.50"/>
                    <measurement group_id="O5" value="-13.05" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.6082) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0104), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-16.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.37</ci_lower_limit>
            <ci_upper_limit>-9.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.6082) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0104), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.30</ci_lower_limit>
            <ci_upper_limit>-15.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.6082) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0104), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.31</ci_lower_limit>
            <ci_upper_limit>-4.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.6082) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0104), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-19.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.21</ci_lower_limit>
            <ci_upper_limit>-12.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 24 for Treatment Naive Patients</title>
        <description>Change from baseline in fasting plasma glucose at week 24 for Treatment Naive patients.</description>
        <time_frame>Baseline and 24 Weeks</time_frame>
        <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all treatment naive patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Treatment Naive: Empagliflozin 25 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Treatment Naive: Empagliflozin 10 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Treatment Naive: Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 24 for Treatment Naive Patients</title>
          <description>Change from baseline in fasting plasma glucose at week 24 for Treatment Naive patients.</description>
          <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all treatment naive patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
          <units>mg/dL change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="132"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.55" spread="2.67"/>
                    <measurement group_id="O2" value="-28.21" spread="2.66"/>
                    <measurement group_id="O3" value="-24.24" spread="2.68"/>
                    <measurement group_id="O4" value="-22.39" spread="2.69"/>
                    <measurement group_id="O5" value="-5.92" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.4591) as linear covariate(s) and baseline eGFR (MDRD) (p=0.7413), geographical region (p=0.1504), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1605</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.74</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.4591) as linear covariate(s) and baseline eGFR (MDRD) (p=0.7413), geographical region (p=0.1504), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1246</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.25</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.4591) as linear covariate(s) and baseline eGFR (MDRD) (p=0.7413), geographical region (p=0.1504), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-23.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.06</ci_lower_limit>
            <ci_upper_limit>-16.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline fasting plasma glucose (p&lt;0.0001), baseline HbA1c (p=0.4591) as linear covariate(s) and baseline eGFR (MDRD) (p=0.7413), geographical region (p=0.1504), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.71</ci_lower_limit>
            <ci_upper_limit>-14.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight for Metformin Background Patients</title>
        <description>Change from baseline in body weight for Metformin Background patients.</description>
        <time_frame>Baseline and 24 Weeks</time_frame>
        <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all Metformin Background patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Metformin Background: Empagliflozin 25 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Metformin Background: Empagliflozin 10 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Metformin Background: Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight for Metformin Background Patients</title>
          <description>Change from baseline in body weight for Metformin Background patients.</description>
          <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all Metformin Background patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
          <units>kg change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="0.31"/>
                    <measurement group_id="O2" value="-2.60" spread="0.30"/>
                    <measurement group_id="O3" value="-3.18" spread="0.30"/>
                    <measurement group_id="O4" value="-2.53" spread="0.30"/>
                    <measurement group_id="O5" value="-0.69" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.1610) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0162), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6604</p_value>
            <p_value_desc>Not an alpha protected test.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.1610) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0162), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.15</ci_lower_limit>
            <ci_upper_limit>-1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.1610) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0162), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8757</p_value>
            <p_value_desc>Not an alpha protected test.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.1610) as linear covariate(s) and baseline eGFR (MDRD) (p=0.3685), geographical region (p=0.0162), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.77</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients</title>
        <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all treatment naive patients randomised to and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Treatment Naive: Empagliflozin 25 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Treatment Naive: Empagliflozin 10 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Treatment Naive: Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients</title>
          <description>Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.</description>
          <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all treatment naive patients randomised to and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
          <units>% change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="132"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.07"/>
                    <measurement group_id="O2" value="-1.24" spread="0.07"/>
                    <measurement group_id="O3" value="-0.95" spread="0.07"/>
                    <measurement group_id="O4" value="-0.83" spread="0.07"/>
                    <measurement group_id="O5" value="-0.67" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.8627), geographical region (p=0.0008), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1785</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.8627), geographical region (p=0.0008), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.8627), geographical region (p=0.0008), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline HbA1c (p&lt;0.0001) as linear covariate(s) and baseline eGFR (MDRD) (p=0.8627), geographical region (p=0.0008), treatment (p&lt;0.0001) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight for Treatment Naive Patients</title>
        <description>Change from baseline in body weight for Treatment Naive patients.</description>
        <time_frame>Baseline and 24 Weeks</time_frame>
        <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all treatment naive patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Treatment Naive: Empagliflozin 25 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Treatment Naive: Empagliflozin 10 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Treatment Naive: Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight for Treatment Naive Patients</title>
          <description>Change from baseline in body weight for Treatment Naive patients.</description>
          <population>Full Analysis Set (FAS) with last observation carried forward (LOCF). FAS - all treatment naive patients randomised and treated who had a baseline and at least 1 on treatment HbA1c value.</population>
          <units>kg change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="132"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="0.36"/>
                    <measurement group_id="O2" value="-2.74" spread="0.36"/>
                    <measurement group_id="O3" value="-2.13" spread="0.36"/>
                    <measurement group_id="O4" value="-2.27" spread="0.37"/>
                    <measurement group_id="O5" value="-0.78" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.0023) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0316), geographical region (p=0.0134), treatment (p=0.0031) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8010</p_value>
            <p_value_desc>Not an alpha protected test.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.0023) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0316), geographical region (p=0.0134), treatment (p=0.0031) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3616</p_value>
            <p_value_desc>Not an alpha protected test.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.0023) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0316), geographical region (p=0.0134), treatment (p=0.0031) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0178</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.23</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Model for Week 24 includes baseline weight (p&lt;0.0001), baseline HbA1c (p=0.0023) as linear covariate(s) and baseline eGFR (MDRD) (p=0.0316), geographical region (p=0.0134), treatment (p=0.0031) as fixed effect(s).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.97</ci_lower_limit>
            <ci_upper_limit>-0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Treat to Target Efficacy Response for Metformin Background Patients</title>
        <description>Occurrence of the treat-to-target efficacy response for Metformin Background patients measured as HbA1c &lt; 7.0% after 24 weeks of treatment for patients with HbA1c &gt;=7.0% at baseline.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Full Analysis Set (FAS) with non-completers considered failures (NCF). FAS- Metformin background patients randomised and treated who had a baseline (HbA1c&gt;= 7% at baseline are included) and at least 1 on treatment HbA1c value with NCF approach, in which missing data due to premature discontinuation of a patient were considered as failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Metformin Background: Empagliflozin 25 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Metformin Background: Empagliflozin 10 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Metformin Background: Linagliptin 5 mg</title>
            <description>Study population on a stable background of metformin defined as pre-treated with metformin (≥1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Treat to Target Efficacy Response for Metformin Background Patients</title>
          <description>Occurrence of the treat-to-target efficacy response for Metformin Background patients measured as HbA1c &lt; 7.0% after 24 weeks of treatment for patients with HbA1c &gt;=7.0% at baseline.</description>
          <population>Full Analysis Set (FAS) with non-completers considered failures (NCF). FAS- Metformin background patients randomised and treated who had a baseline (HbA1c&gt;= 7% at baseline are included) and at least 1 on treatment HbA1c value with NCF approach, in which missing data due to premature discontinuation of a patient were considered as failure.</population>
          <units>% of patients satisfying HbA1c &lt;7.0%</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="125"/>
                <count group_id="O5" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="52.6" upper_limit="70.4"/>
                    <measurement group_id="O2" value="57.8" lower_limit="48.8" upper_limit="66.5"/>
                    <measurement group_id="O3" value="32.6" lower_limit="24.7" upper_limit="41.3"/>
                    <measurement group_id="O4" value="28.0" lower_limit="20.3" upper_limit="36.7"/>
                    <measurement group_id="O5" value="36.1" lower_limit="27.5" upper_limit="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.191</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.319</ci_lower_limit>
            <ci_upper_limit>7.573</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.500</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.474</ci_lower_limit>
            <ci_upper_limit>8.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.495</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.920</ci_lower_limit>
            <ci_upper_limit>6.363</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.795</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.562</ci_lower_limit>
            <ci_upper_limit>5.001</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients</title>
        <description>Occurrence of the treat-to-target efficacy response for Treatment Naive patients measured as HbA1c &lt; 7.0% after 24 weeks of treatment for patients with HbA1c &gt;=7.0% at baseline.</description>
        <time_frame>24 Weeks</time_frame>
        <population>Full Analysis Set (FAS) with non-completers considered failures (NCF). FAS-treatment naive patients randomised and treated who had a baseline (HbA1c&gt;= 7% at baseline are included) and at least 1 on treatment HbA1c value with NCF approach, in which missing data due to premature discontinuation of a patient were considered as failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O2">
            <title>Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O3">
            <title>Treatment Naive: Empagliflozin 25 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O4">
            <title>Treatment Naive: Empagliflozin 10 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
          </group>
          <group group_id="O5">
            <title>Treatment Naive: Linagliptin 5 mg</title>
            <description>Study population treatment naive defined as an absence of any oral antidiabetic therapy, GLP-1 analog or insulin for 12 weeks prior to randomisation.
Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients</title>
          <description>Occurrence of the treat-to-target efficacy response for Treatment Naive patients measured as HbA1c &lt; 7.0% after 24 weeks of treatment for patients with HbA1c &gt;=7.0% at baseline.</description>
          <population>Full Analysis Set (FAS) with non-completers considered failures (NCF). FAS-treatment naive patients randomised and treated who had a baseline (HbA1c&gt;= 7% at baseline are included) and at least 1 on treatment HbA1c value with NCF approach, in which missing data due to premature discontinuation of a patient were considered as failure.</population>
          <units>% of patients satisfying HbA1c &lt;7.0%</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" lower_limit="46.1" upper_limit="64.4"/>
                    <measurement group_id="O2" value="62.3" lower_limit="53.1" upper_limit="70.9"/>
                    <measurement group_id="O3" value="41.5" lower_limit="32.5" upper_limit="51.0"/>
                    <measurement group_id="O4" value="38.8" lower_limit="30.1" upper_limit="48.1"/>
                    <measurement group_id="O5" value="32.3" lower_limit="24.3" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0224</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.893</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.095</ci_lower_limit>
            <ci_upper_limit>3.274</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.961</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.697</ci_lower_limit>
            <ci_upper_limit>5.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.768</ci_lower_limit>
            <ci_upper_limit>5.314</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Logistic regression includes treatment, baseline eGFR (MDRD), geographical region and baseline HbA1c.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.303</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.462</ci_lower_limit>
            <ci_upper_limit>7.522</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first trial medication intake until 7 days after last drug intake during the 52-week study period</time_frame>
      <desc>One patient was randomized to treatment with Empa/Lina 25/5 but was treated with Empa 10 from the start of trial for 6 weeks. For efficacy, the patient was analyzed as randomized (Empa/Lina 25/5) and for safety the patient was analyzed as first medication taken (Empa 10).</desc>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin 25 mg/Linagliptin 5 mg</title>
          <description>Test product: Empagliflozin/linagliptin FDC tablets dose: 25 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10 mg/Linagliptin 5 mg</title>
          <description>Test product: Empagliflozin/linagliptin FDC tablets dose: 10 mg/5 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 25 mg</title>
          <description>Reference therapy 1: Empagliflozin tablets dose: 25 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="E4">
          <title>Empagliflozin 10 mg</title>
          <description>Reference therapy 1: Empagliflozin tablets dose: 10 mg q.d. mode of admin.: Oral</description>
        </group>
        <group group_id="E5">
          <title>Linagliptin 5 mg</title>
          <description>Reference therapy 2: Linagliptin tablets dose: 5 mg q.d. mode of admin.: Oral</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenoid cystic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="94" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="276"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="275"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

